Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis.
OBJECTIVE
Non-alcoholic fatty liver disease (NAFLD) is associated with a higher risk of cardiovascular disease, but no data exist about the relation between NAFLD and adverse outcomes in persons with acute coronary syndromes (ACS). We evaluated elevated serum alanine aminotransferase (ALT) as a marker of NAFLD, in association adverse outcomes following ACS.


METHODS
We conducted a retrospective cohort study of participants enrolled in the Global Registry of Acute Coronary Events (GRACE) admitted for ACS to St Michael's Hospital, Toronto, between 1999 and 2007. Multivariable linear regression was used to determine the change in maximum measured cardiac troponin I (cTnI) per each 1 IU/l increase in serum ALT concentration. The association between an elevated ALT >90th centile, and adverse outcomes in-hospital and at 6 months were calculated using multiple logistic regression analyses, adjusting for age, sex, body mass index, serum creatinine, glucose, triglycerides and LDL-C, as well as chronic statin or other lipid-lowering agent use.


RESULTS
528 participants were included. Each 1 IU/l increase in ALT was associated with an increase in maximum measured cTnI of 0.16 µg/l (95% CI 0.10 to 0.22). An elevated ALT concentration >90th percentile was associated with a maximum measured cTnI in the highest quartile (adjusted OR 7.07, 95% CI 1.83 to 27.37). An elevated ALT >90th percentile was also significantly associated with all-cause mortality in-hospital, and up to 6 months after discharge (adjusted OR 8.96, 95% CI 3.28 to 24.49).


CONCLUSIONS
NAFLD, determined by an elevated serum ALT, is associated with a higher risk of adverse outcomes in persons with ACS. Whether ALT is a valid and independent prognostic marker in ACS remains to be determined.
Faculty of Health Sciences, McMaster University, Hamilton,  Ontario, Canada.
Lavanya
L
Ravichandran
Division of Cardiology, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada; Canadian Heart Research Centre, Toronto,  Ontario, Canada.
Shaun G
SG
Goodman
Division of Cardiology, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
Andrew T
AT
Yan
Canadian Heart Research Centre, Toronto,  Ontario, Canada.
Aurora
A
Mendelsohn
Division of Cardiology, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada; Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Joel G
JG
Ray
Coronary Artery Disease; Metabolic Medicine